Flanders Backs ActoGeniX

ActoGeniX, a Dutch biopharmaceutical developer and spin-off from VIB and Ghent University, has secured a �3.1 million ($4.2 million) grant from the Flanders government. The money follows a Series A round where it raised �20 million from Biotech Flanders, GIMV, Life Sciences Partners, Aescap Venture, Baekeland Fonds and Ventech, reports vw. www.actogenix.com